Irina Zabbarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irina Zabbarova has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Kanai
Department of Medicine Renal‐Electrolyte Division, University of Pittsburgh Pittsburgh Pennsylvania USA
6 shared publications - Youko Ikeda
Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, USA
5 shared publications - Pradeep Tyagi
Department of Urology University of Pittsburgh Pittsburgh Pennsylvania USA
4 shared publications - Christopher Henry Fry
School of Physiology, Pharmacology & Neuroscience University of Bristol Bristol UK
3 shared publications - Lori Ann Birder
Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
3 shared publications - Marcus John Drake
Department of Surgery and Cancer, Imperial College, London, UK
3 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Elsevier in Continence
- Vol. 18
Adenosine receptor-coupled modulation of ATP release from isolated urothelial cells of mouse bladder
- 11 March 2026
- Published by Elsevier in Continence
- Vol. 18
Open AccessAdenosine receptor-coupled modulation of ATP release from isolated urothelial cells of mouse bladder
- Open Access
- 11 October 2025
- Published by Elsevier in Continence
- Vol. 16
Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia
- 11 October 2025
- Published by Elsevier in Continence
- Vol. 16
Open AccessEndogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia
- Open Access
- 21 March 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (4) , 114007
Insulin receptor signaling engages bladder urothelial defenses that limit urinary tract infection
- 21 March 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (4) , 114007
Open AccessInsulin receptor signaling engages bladder urothelial defenses that limit urinary tract infection
- Open Access
- 8 July 2022
- Published by Elsevier in Continence
- Vol. 2, 100289
200 SOLUBLE GUANYLATE CYCLASE ACTIVATOR, CINACIGUAT, PROMOTES REVASCULARIZATION OF THE CONTUSED SPINAL CORD TO TREAT SPINAL CORD INJURY INDUCED DYSFUNCTION
- 8 July 2022
- Published by Elsevier in Continence
- Vol. 2, 100289
Open Access200 SOLUBLE GUANYLATE CYCLASE ACTIVATOR, CINACIGUAT, PROMOTES REVASCULARIZATION OF THE CONTUSED SPINAL CORD TO TREAT SPINAL CORD INJURY INDUCED DYSFUNCTION
- Open Access
- 25 May 2022
- Published by Elsevier in Continence
- Vol. 2
Effects of vasopressin receptor agonists on detrusor smooth muscle tone in young and aged bladders: Implications for nocturia treatment
- 25 May 2022
- Published by Elsevier in Continence
- Vol. 2
Open AccessEffects of vasopressin receptor agonists on detrusor smooth muscle tone in young and aged bladders: Implications for nocturia treatment
- Open Access
- 18 March 2022
- Published by Elsevier in Continence
- Vol. 1
Targeting neurotrophin and nitric oxide signaling to treat spinal cord injury and associated neurogenic bladder overactivity
- 18 March 2022
- Published by Elsevier in Continence
- Vol. 1
Open AccessTargeting neurotrophin and nitric oxide signaling to treat spinal cord injury and associated neurogenic bladder overactivity
- 15 February 2022
- Published by Wiley in The Journal of Pathology
- Vol. 256 (4) , 442-454
Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator
Benign prostatic hyperplasia (BPH) is a feature of ageing males. Up to half demonstrate bladder outlet obstruction (BOO) with associated lower urinary tract symptoms (LUTS) including bladder overactivity. Current therapies to reduce obstruction, such as α1‐adrenoceptor antagonists and 5α‐reductase inhibitors, are not effective in all patients. The phosphodiesterase‐5 inhibitor (PDE5I) tadalafil is also approved to treat BPH and LUTS, suggesting a role for nitric oxide (NO•), soluble guanylate cyclase (sGC), and cGMP signalling pathways. However, PDE5I refractoriness can develop for reasons including nitrergic nerve damage and decreased NO• production, or inflammation‐related oxidation of the sGC haem group, normally maintained in a reduced state by the cofactor cytochrome‐b5‐reductase 3 (CYB5R3). sGC activators, such as cinaciguat (BAY 58‐2667), have been developed to enhance sGC activity in the absence of NO• or when sGC is oxidised. Accordingly, their effects on the prostate and LUT function of aged mice were evaluated. Aged mice (≥24 months) demonstrated a functional BPH/BOO phenotype, compared with adult animals (2–12 months), with low, delayed voiding responses and elevated intravesical pressures as measured by telemetric cystometry. This was consistent with outflow tract histological and molecular data that showed urethral constriction, increased prostate weight, greater collagen deposition, and cellular hyperplasia. All changes in aged animals were attenuated by daily oral treatment with cinaciguat for 2 weeks, without effect on serum testosterone levels. Cinaciguat had only transient (1 h) cardiovascular effects with oral gavage, suggesting a positive safety profile. The benefit of cinaciguat was suggested by its reversal of an overactive cystometric profile in CYB5R3 smooth muscle knockout mice that mirrors a profile of oxidative dysfunction where PDE5I may not be effective. Thus, the aged male mouse is a suitable model for BPH‐induced BOO and cinaciguat has a demonstrated ability to reduce prostate‐induced obstruction and consequent effects on bladder function. © 2021 The Pathological Society of Great Britain and Ireland.
- 15 February 2022
- Published by Wiley in The Journal of Pathology
- Vol. 256 (4) , 442-454
Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator
Benign prostatic hyperplasia (BPH) is a feature of ageing males. Up to half demonstrate bladder outlet obstruction (BOO) with associated lower urinary tract symptoms (LUTS) including bladder overactivity. Current therapies to reduce obstruction, such as α1‐adrenoceptor antagonists and 5α‐reductase inhibitors, are not effective in all patients. The phosphodiesterase‐5 inhibitor (PDE5I) tadalafil is also approved to treat BPH and LUTS, suggesting a role for nitric oxide (NO•), soluble guanylate cyclase (sGC), and cGMP signalling pathways. However, PDE5I refractoriness can develop for reasons including nitrergic nerve damage and decreased NO• production, or inflammation‐related oxidation of the sGC haem group, normally maintained in a reduced state by the cofactor cytochrome‐b5‐reductase 3 (CYB5R3). sGC activators, such as cinaciguat (BAY 58‐2667), have been developed to enhance sGC activity in the absence of NO• or when sGC is oxidised. Accordingly, their effects on the prostate and LUT function of aged mice were evaluated. Aged mice (≥24 months) demonstrated a functional BPH/BOO phenotype, compared with adult animals (2–12 months), with low, delayed voiding responses and elevated intravesical pressures as measured by telemetric cystometry. This was consistent with outflow tract histological and molecular data that showed urethral constriction, increased prostate weight, greater collagen deposition, and cellular hyperplasia. All changes in aged animals were attenuated by daily oral treatment with cinaciguat for 2 weeks, without effect on serum testosterone levels. Cinaciguat had only transient (1 h) cardiovascular effects with oral gavage, suggesting a positive safety profile. The benefit of cinaciguat was suggested by its reversal of an overactive cystometric profile in CYB5R3 smooth muscle knockout mice that mirrors a profile of oxidative dysfunction where PDE5I may not be effective. Thus, the aged male mouse is a suitable model for BPH‐induced BOO and cinaciguat has a demonstrated ability to reduce prostate‐induced obstruction and consequent effects on bladder function. © 2021 The Pathological Society of Great Britain and Ireland.